In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with ...

U.S. stock futures rose on Monday after Friday’s sharp fall as investors digested the tariff updates and earnings reports.

This article is a text version of a Wall Street Journal newsletter published earlier today.

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

The focus of Wall Street investors in the week ahead will be primarily on expected reciprocal trade tariffs by US President ...

Leadership expansion underscores Ataccama’s commitment to customer success, partner ecosystem growth, and innovative data solutionsBOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ataccama, the data trust ...

Wall Street also benefited from some dip-buying after clocking steep falls on Friday, as Trump flagged plans to impose tariffs on U.S. imports to match levies from U.S. trading partners on goods ...

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: ...